Mestinon (Pyridostigmine Bromide)

Pyridostigmine inhibits the enzyme acetylcholinesterase, which normally breaks down acetylcholine at the neuromuscular junction. The inhibition raises acetylcholine levels, allowing more sustained stimulation of nicotinic receptors on skeletal muscle fibers, thereby improving muscle contraction strength.

The dosage of Mestinon is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, severity of symptoms, renal function, and response to therapy. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for pyridostigmine in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and benefits with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mestinon belongs to the class of reversible acetylcholinesterase inhibitors, similar to neostigmine but with a longer duration of action and better oral bioavailability. Compared with immunosuppressive therapies, it provides symptomatic relief without altering the underlying immune response, making it a first‑line symptomatic option.

Mestinon tablets should be stored at temperatures below 25 °C, in their original container, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Mestinon is taken orally, usually with a glass of water. It can be taken with or without food, but consistent timing relative to meals helps maintain stable blood levels. Patients should not crush or chew the tablets unless specifically instructed by a healthcare professional.

The most critical risks include cholinergic crisis, which can present as severe muscle weakness, respiratory failure, and bradycardia, as well as bronchospasm and seizures. Prompt medical attention is required if any of these symptoms develop.

Mestinon is contraindicated in individuals with known hypersensitivity to pyridostigmine or any component of the formulation. Patients with severe asthma, chronic obstructive pulmonary disease, or those taking potent anticholinergic drugs should avoid it unless closely supervised by a physician.